The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Patients in the TRANSCEND FL study received liso-cel after lymphodepleting chemotherapy (LDC). Bridging therapy was allowed with reconfirmation of PET-positive disease before LDC.
Prof. Charlie Craddock, CBE, discusses what to expect at the first SOHO UK, which will be held 3–4 March 2026 in London at
Live session held on February 11, 2026, from 2:00–2:30 PM CST with speaker Tara Graff presenting on "Implementing Bispecific Antibodies in Community Practice."
In this video from SOHO Asia 2026, Dr. DiPersio discusses highlights from the acute myeloid leukemia session with Drs. Andrew Wei, Naval Daver,
Orca-T, an investigational allogeneic T-cell immunotherapy, led to better quality-of-life outcomes and lower healthcare resource use than standard treatment with conventional allograft with
Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendritic cell neoplasm, according to
The first session of the Community Oncology Brown Bag Series hosted by SOHO Insider was held on January 20, 2026, and featured guest
“I’m quite emotional about this presidency,” Dr. Santini said in a Pathways & Perspectives interview with SOHO Insider. “I’m incredibly honored to become
In this podcast episode recorded at the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Megan Melody, MD, from Tampa
